Mark Vincent
Director/Board Member presso APTOSE BIOSCIENCES INC.
Patrimonio netto: 719 $ in data 31/03/2024
Posizioni attive di Mark Vincent
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| APTOSE BIOSCIENCES INC. | Director/Board Member | 19/09/2007 | - |
| Independent Dir/Board Member | 19/09/2007 | - | |
| Sarissa, Inc. | Director/Board Member | 18/01/2011 | - |
| Chief Executive Officer | 01/01/2000 | - | |
| Founder | 01/01/2000 | - | |
| University of Western Ontario | Corporate Officer/Principal | 01/01/2008 | - |
Storia della carriera di Mark Vincent
Precedenti posizioni note di Mark Vincent
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Director/Board Member | - | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01/01/2000 | - |
Formazione di Mark Vincent
| University of Cape Town | Doctorate Degree |
Statistiche
Distribuzione geografica
| Canada | 4 |
| Stati Uniti | 2 |
| Regno Unito | 2 |
Posizioni
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Aziende private | 3 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. |
- Borsa valori
- Insiders
- Mark Vincent
- Esperienza
